Epigenetic regulation of AURKA by miR-4715-3p in upper gastrointestinal cancers.


Journal

Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288

Informations de publication

Date de publication:
18 11 2019
Historique:
received: 17 07 2019
accepted: 29 10 2019
entrez: 20 11 2019
pubmed: 20 11 2019
medline: 15 12 2020
Statut: epublish

Résumé

Aurora kinase A (AURKA) is frequently overexpressed in several cancers. miRNA sequencing and bioinformatics analysis indicated significant downregulation of miR-4715-3p. We found that miR-4715-3p has putative binding sites on the 3UTR region of AURKA. Upper gastrointestinal adenocarcinoma (UGC) tissue samples and cell models demonstrated significant overexpression of AURKA with downregulation of miR-4715-3p. Luciferase reporter assays confirmed binding of miR-4715-3p on the 3UTR region of AURKA. miR-4715-3p mediated a reduction in AURKA levels leading to G2/M delay, chromosomal polyploidy, and cell death. We also detected a remarkable decrease in GPX4, an inhibitor of ferroptosis, with an increase in cleaved PARP and caspase-3. Inhibition of AURKA using siRNA produced similar results, suggesting a possible link between AURKA and GPX4. Analysis of UGC samples and cell models demonstrated increased methylation levels of several CpG nucleotides upstream of miR-4715-3p. 5-Aza-2'-deoxycytidine induced demethylation of several CpG nucleotides, restoring miR-4715-3p expression, leading to downregulation of AURKA. In conclusion, our data identified a novel epigenetic mechanism mediating silencing of miR-4715-3p and induction of AURKA in UGCs. Inhibition of AURKA or reconstitution of miR-4715-3p inhibited GPX4 and induced cell death, suggesting a link between AURKA and ferroptosis.

Identifiants

pubmed: 31740746
doi: 10.1038/s41598-019-53174-6
pii: 10.1038/s41598-019-53174-6
pmc: PMC6861278
doi:

Substances chimiques

3' Untranslated Regions 0
Antineoplastic Agents 0
MicroRNAs 0
Phospholipid Hydroperoxide Glutathione Peroxidase EC 1.11.1.12
AURKA protein, human EC 2.7.11.1
Aurora Kinase A EC 2.7.11.1
Cisplatin Q20Q21Q62J

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, Non-P.H.S.

Langues

eng

Sous-ensembles de citation

IM

Pagination

16970

Subventions

Organisme : BLRD VA
ID : I01 BX001179
Pays : United States
Organisme : BLRD VA
ID : IK6 BX003787
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA240139
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA131225
Pays : United States

Références

Neoplasia. 2017 Dec;19(12):1022-1032
pubmed: 29144989
Clin Cancer Res. 2014 Jan 1;20(1):76-86
pubmed: 24240108
Gastroenterology. 2013 Dec;145(6):1312-22.e1-8
pubmed: 23993973
J Pathol Clin Res. 2014 Nov 07;1(1):33-40
pubmed: 27499891
Clin Cancer Res. 2017 Jul 15;23(14):3756-3768
pubmed: 28073841
Cancer Lett. 2006 Oct 28;242(2):273-9
pubmed: 16412566
Curr Genomics. 2010 Nov;11(7):537-61
pubmed: 21532838
Oncogene. 2009 Feb 12;28(6):866-75
pubmed: 19060929
Proc Natl Acad Sci U S A. 2016 Nov 29;113(48):13726-13731
pubmed: 27837025
Cell Death Dis. 2016 Jul 21;7:e2307
pubmed: 27441659
Cancer Cell. 2012 Feb 14;21(2):196-211
pubmed: 22340593
Oncotarget. 2016 Aug 2;7(31):49322-49333
pubmed: 27384994
Nature. 2017 Jan 12;541(7636):169-175
pubmed: 28052061
Genom Data. 2015 Nov 27;7:92-3
pubmed: 26981373
Nat Med. 2016 Jul;22(7):744-53
pubmed: 27213815
Clin Cancer Res. 2003 Mar;9(3):991-7
pubmed: 12631597
Oncogenesis. 2017 Feb 20;6(2):e298
pubmed: 28218735
Cancer Res. 2010 Jun 1;70(11):4655-65
pubmed: 20460511
Mol Cancer. 2012 Jan 30;11:5
pubmed: 22289355
CA Cancer J Clin. 2019 Jan;69(1):7-34
pubmed: 30620402
CA Cancer J Clin. 2011 Mar-Apr;61(2):69-90
pubmed: 21296855
Curr Cancer Drug Targets. 2017;17(4):386-401
pubmed: 27396604
Oncotarget. 2016 May 31;7(22):33152-64
pubmed: 27121204
Cancer. 2013 Feb 15;119(4):904-14
pubmed: 22972611
J Transl Med. 2014 Jul 31;12:200
pubmed: 25082261
Cell. 2014 Jan 16;156(1-2):317-331
pubmed: 24439385
Oncol Rep. 2004 Sep;12(3):593-9
pubmed: 15289843
Sci Rep. 2018 Jun 15;8(1):9227
pubmed: 29907753
Nature. 2014 Sep 11;513(7517):202-9
pubmed: 25079317
Curr Top Microbiol Immunol. 2017;403:143-170
pubmed: 28204974
Onco Targets Ther. 2015 Dec 07;8:3639-48
pubmed: 26675712
Nat Cell Biol. 2014 Dec;16(12):1180-91
pubmed: 25402683
Theranostics. 2018 Feb 12;8(6):1740-1751
pubmed: 29556353
Mol Oncol. 2017 Aug;11(8):981-995
pubmed: 28417568
Oncol Rep. 2007 May;17(5):1083-8
pubmed: 17390048
Nat Rev Cancer. 2017 Jan 27;17(2):93-115
pubmed: 28127048
Hum Pathol. 2013 Jan;44(1):77-86
pubmed: 22939955
J Transl Med. 2016 May 20;14(1):143
pubmed: 27197967
PLoS One. 2015 Mar 04;10(3):e0117714
pubmed: 25739101
Nat Commun. 2016 Jan 19;7:10180
pubmed: 26782714
Gastroenterology. 2019 Mar;156(4):1127-1139.e8
pubmed: 30502323
J Invest Dermatol. 2017 Jun;137(6):1297-1310
pubmed: 28188776
Cancer Res. 1999 May 1;59(9):2041-4
pubmed: 10232583
Gut. 2009 Jan;58(1):5-15
pubmed: 18664505
J Pathol Transl Med. 2017 Jan;51(1):32-39
pubmed: 28013532
Cell Rep. 2017 Aug 15;20(7):1692-1704
pubmed: 28813679
Cancer Res. 2008 Nov 1;68(21):8998-9004
pubmed: 18974145
Nature. 2019 Aug;572(7769):402-406
pubmed: 31341276
Epigenetics. 2014 Jun;9(6):910-7
pubmed: 24686393
IUBMB Life. 2016 Aug;68(8):634-44
pubmed: 27270838
Mol Cancer. 2015 May 20;14:106
pubmed: 25987188
Int J Biochem Cell Biol. 2018 May;98:89-92
pubmed: 29544896
EMBO J. 1998 Jun 1;17(11):3052-65
pubmed: 9606188
Cell. 2004 Jan 23;116(2):281-97
pubmed: 14744438
Blood. 2010 Jun 24;115(25):5202-13
pubmed: 20382844
J Natl Cancer Inst. 2000 Apr 5;92(7):569-73
pubmed: 10749913
Nat Rev Cancer. 2006 Nov;6(11):857-66
pubmed: 17060945
Sci Rep. 2017 Jan 19;7:40729
pubmed: 28102292
Int J Oncol. 2019 Jan;54(1):53-64
pubmed: 30387838
J Clin Invest. 2013 Jun;123(6):2502-8
pubmed: 23676460

Auteurs

Ahmed Gomaa (A)

Department of Surgery, University of Miami Miller School of Medicine, Miami, Florida, USA.

Dunfa Peng (D)

Department of Surgery, University of Miami Miller School of Medicine, Miami, Florida, USA.

Zheng Chen (Z)

Department of Surgery, University of Miami Miller School of Medicine, Miami, Florida, USA.
Department of Veterans Affairs, Miami Healthcare System, Miami, Florida, USA.

Mohammed Soutto (M)

Department of Surgery, University of Miami Miller School of Medicine, Miami, Florida, USA.
Department of Veterans Affairs, Miami Healthcare System, Miami, Florida, USA.

Khaled Abouelezz (K)

Department of Medicine, University of Miami Miller School of Medicine, Miami, Florida, USA.

Alejandro Corvalan (A)

Advanced Center for Chronic Disease, School of Medicine, Pontificia Universidad Catolica de Chile, Santiago, Chile.

Wael El-Rifai (W)

Department of Surgery, University of Miami Miller School of Medicine, Miami, Florida, USA. wxe45@miami.edu.
Department of Veterans Affairs, Miami Healthcare System, Miami, Florida, USA. wxe45@miami.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH